Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999, 5 (2): 157-163. 10.1038/5517.
Article
CAS
PubMed
Google Scholar
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999, 104 (2): 155-162. 10.1172/JCI6926.
Article
CAS
PubMed
PubMed Central
Google Scholar
Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL: Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 2000, 165 (5): 2886-2894.
Article
CAS
PubMed
Google Scholar
Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, et al: Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 2003, 63 (10): 2369-2372.
CAS
PubMed
Google Scholar
Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P, et al: Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther. 2006, 17 (12): 1225-1240. 10.1089/hum.2006.17.1225.
Article
CAS
PubMed
Google Scholar
Dong F, Wang L, Davis JJ, Hu W, Zhang L, et al: Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res. 2006, 12 (17): 5224-5230. 10.1158/1078-0432.CCR-06-0244.
Article
CAS
PubMed
PubMed Central
Google Scholar
Griffith TS, Broghammer EL: Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther. 2001, 4 (3): 257-266. 10.1006/mthe.2001.0439.
Article
CAS
PubMed
Google Scholar
Kagawa S, He C, Gu J, Koch P, Rha SJ, et al: Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001, 61 (8): 3330-3338.
CAS
PubMed
Google Scholar
Kock N, Kasmieh R, Weissleder R, Shah K: Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia. 2007, 9 (5): 435-442. 10.1593/neo.07223.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee J, Hampl M, Albert P, Fine HA: Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia. 2002, 4 (4): 312-323. 10.1038/sj.neo.7900245.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, et al: Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med. 2007, 9 (6): 440-451. 10.1002/jgm.1036.
Article
CAS
PubMed
Google Scholar
Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, et al: Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther. 2003, 10 (7): 540-548. 10.1038/sj.cgt.7700597.
Article
CAS
PubMed
Google Scholar
Voelkel-Johnson C, King DL, Norris JS: Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002, 9 (2): 164-172. 10.1038/sj.cgt.7700420.
Article
CAS
PubMed
Google Scholar
Wenger T, Mattern J, Haas TL, Sprick MR, Walczak H, et al: Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther. 2007, 14 (3): 316-326. 10.1038/sj.cgt.7701016.
Article
CAS
PubMed
Google Scholar
Yang F, Shi P, Xi X, Yi S, Li H, et al: Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC). Med Oncol. 2006, 23 (2): 191-204. 10.1385/MO:23:2:191.
Article
CAS
PubMed
Google Scholar
Zhang Y, Ma H, Zhang J, Liu S, Liu Y, et al: AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 2008, 82 (23–24): 1154-1161.
Article
CAS
PubMed
Google Scholar
Ma H, Liu Y, Liu S, Xu R, Zheng D: Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology. 2005, 42 (6): 1355-1363. 10.1002/hep.20918.
Article
CAS
PubMed
Google Scholar
Shi J, Zheng D, Liu Y, Sham MH, Tam P, et al: Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 2005, 65 (5): 1687-1692. 10.1158/0008-5472.CAN-04-2749.
Article
CAS
PubMed
Google Scholar
Ma H, Liu Y, Liu S, Kung HF, Sun X, et al: Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer. 2005, 116 (2): 314-321. 10.1002/ijc.20982.
Article
CAS
PubMed
Google Scholar
Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, et al: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000, 6 (5): 564-567. 10.1038/75045.
Article
CAS
PubMed
Google Scholar
Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, et al: Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000, 60 (3): 553-559.
CAS
PubMed
Google Scholar
Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, et al: Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet. 2000, 356 (9232): 827-828. 10.1016/S0140-6736(00)02659-3.
Article
CAS
PubMed
Google Scholar
Nesterov A, Ivashchenko Y, Kraft AS: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene. 2002, 21 (7): 1135-1140. 10.1038/sj.onc.1205151.
Article
CAS
PubMed
Google Scholar
Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, et al: Acceleration of human neutrophil apoptosis by TRAIL. J Immunol. 2003, 170 (2): 1027-1033.
Article
CAS
PubMed
Google Scholar
Schaefer U, Voloshanenko O, Willen D, Walczak H: TRAIL: a multifunctional cytokine. Front Biosci. 2007, 12: 3813-3824. 10.2741/2354.
Article
CAS
PubMed
Google Scholar
Thorburn A: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J Thorac Oncol. 2007, 2 (6): 461-465. 10.1097/JTO.0b013e31805fea64.
Article
PubMed
Google Scholar
Tang W, Wang W, Zhang Y, Liu S, Liu Y, et al: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J. 2009, 276 (2): 581-593. 10.1111/j.1742-4658.2008.06809.x.
Article
CAS
PubMed
Google Scholar
Tang W, Wang W, Zhang Y, Liu S, Liu Y, et al: TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner. Cell Res. 2009, 19 (6): 758-767. 10.1038/cr.2009.57.
Article
CAS
PubMed
Google Scholar
Kahraman A, Barreyro FJ, Bronk SF, Werneburg NW, Mott JL, et al: TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology. 2008
Google Scholar
Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, et al: Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther. 2005, 12 (2): 189-211. 10.1016/j.ymthe.2005.03.022.
Article
CAS
PubMed
PubMed Central
Google Scholar